<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03991143</url>
  </required_header>
  <id_info>
    <org_study_id>ATH3G10-006</org_study_id>
    <secondary_id>2018-003676-12</secondary_id>
    <nct_id>NCT03991143</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Tolerability of ATH3G10 in Patients With ST-elevation Myocardial Infarction</brief_title>
  <official_title>A Phase IIa, Placebo-controlled, Double Blind, Randomised Multicentre Pilot Study to Investigate the Efficacy, Safety and Tolerability of the Monoclonal Antibody ATH3G10 in Patients With ST-elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Athera Biotechnologies AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Athera Biotechnologies AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with ST-segment elevation myocardial infarction (STEMI) that have suffered a major
      anterior wall infarction or where coronary blood flow is less than normal in spite of
      successful percutaneous coronary intervention (PCI) have a poor prognosis. There are today no
      medical treatments that specifically reduce risk in these patients. The acute inflammatory
      reaction in conjunction with a STEMI and reperfusion by PCI determines the final size of the
      infarction and the signals leading to left ventricular remodelling.

      This study is designed to assess the efficacy and safety of single intravenous injection with
      ATH3G10, a fully human IgG1 antibody against phosphorylcholine, in high-risk subjects with
      STEMI. ATH3G10 aims to reduce inflammation and thereby infarction size and remodeling.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 29, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Actual">July 6, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular remodelling</measure>
    <time_frame>From Visit2 (day 3) to visit 3 (day 90)</time_frame>
    <description>Change in Left Ventricular End-Diastolic Volume index (LV EDVi)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial Salvage index (MSi)</measure>
    <time_frame>Visit 2 (day 3)</time_frame>
    <description>Effects on myocardial salvage index (MSi) measured by MRI</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and tolerability]</measure>
    <time_frame>From baseline (Visit 1, day 1) to visit 3 (day 90)</time_frame>
    <description>Assessment of Safety and Tolerability based on incidence of AEs/SAEs</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>ST Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>ATH3G10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phosphorylcholine human monoclonal antibody (ATH3G10)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to ATH3G10, 0.9% sodium chloride</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATH3G10</intervention_name>
    <description>intravenous</description>
    <arm_group_label>ATH3G10</arm_group_label>
    <other_name>PC-mAB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>intravenous</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>0.9% sodium chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute myocardial infarction with ST elevation at the J-point in two contiguous leads

          -  Start of PCI less than 4 hours after symptom onset.

        Exclusion Criteria:

          -  Cardiogenic chock, non-compensated acute heart failure and/or pulmonary edema.

          -  Previous major vascular intervention within the last 4 weeks.

          -  History of an infarct in the same artery that is currently affected.

          -  Conditions contraindicating MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Cardiology, Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>75237</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 14, 2019</study_first_submitted>
  <study_first_submitted_qc>June 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2019</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

